Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | CTSS | P25774 | 5/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398507 | 1.00 | TACR1 (0.55) | TACR1CTSKCTSSCTSLCTSB | |
| SCHEMBL28518198 | 0.86 | TACR1 (0.53) | TACR1CTSKCTSSCTSLCTSB | |
| SCHEMBL6560581 | 0.86 | CTSS (0.64) | TACR1CTSKCTSSCTSLCTSB | |
| SCHEMBL6560575 | 0.86 | CTSS (0.64) | TACR1CTSKCTSSCTSLCTSB | |
| SCHEMBL15527971 | 0.86 | CTSK (0.63) | CTSKCTSSCTSLCTSB | |
| SCHEMBL7233479 | 0.84 | SYK (0.55) | TACR1CTSKCTSSCTSLCTSB | |
| SCHEMBL201710 | 0.82 | PPARA (0.57) | TACR1CTSKCTSSCTSLCTSB | |
| SCHEMBL220648 | 0.82 | TACR1 (0.68) | TACR1CTSKCTSSCTSLCTSB | |
| SCHEMBL295865 | 0.82 | PPARA (0.57) | TACR1CTSKCTSSCTSLCTSB | |
| SCHEMBL7372270 | 0.82 | TACR1 (0.68) | TACR1CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586442-B2 | Benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | CARNIATO DENIS (FR) | 2003-07-01 | — | — | US | disclosed |
| EP-1133491-B1 | NOVEL BENZOFURANE DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2003-02-19 | — | — | EP | disclosed |
| US-20020187976-A1 | New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2002-12-12 | — | — | US | disclosed |
| US-6458801-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND ITS PRODRUG USEFUL FOR TREATING OSTEOPOROSIS. | AVENTIS PHARMA S.A. (FR) | 2002-10-01 | — | — | US | disclosed |
| EP-1133491-A1 | NOVEL BENZOFURANE DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000031070-A1 | NOVEL BENZOFURANE DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187976-A1 | New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | CYP2F1, CYP2C19, CYP2B6 | TACR1 3775/4885CTSK 884/4885CTSS 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.